Patents Assigned to Monash University
-
Publication number: 20240151710Abstract: The invention relates to the field of medical diagnostics. In particular, it relates to compositions, methods and kits for detecting immune cells for diagnosis of allergy, for monitoring of vaccination responses, for determining immune response to pathogens and of treatment efficacy of allergen immunotherapy. For example, the invention provides a method of determining allergic reactivity in a subject, the method comprising, providing a sample from a subject, contacting the sample with a recombinant or synthetic allergen linked to a detectable label in conditions for permitting the binding of the allergen to an IgE molecule present in the sample, determining the binding of the allergen to an IgE molecule in the sample by detecting the label, wherein the detection of the label indicates the subject has allergic reactivity.Type: ApplicationFiled: October 16, 2020Publication date: May 9, 2024Applicants: MONASH UNIVERSITY, ALFRED HEALTH, THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTDInventors: MENNO VAN ZELM, ROBYN O'HEHIR, MARK HOGARTH
-
Patent number: 11976343Abstract: An aluminium based alloy, and a method for production of components by additive manufacturing (AM) or other rapid solidification process with the alloy, is based on the alloy having a composition with from 2.01 wt % to 15.0 wt % manganese, from 0.3 wt % to 2.0 wt % scandium, with a balance apart from minor alloy elements and incidental impurities of aluminium.Type: GrantFiled: July 28, 2023Date of Patent: May 7, 2024Assignee: MONASH UNIVERSITYInventors: Paul Rometsch, Xinhua Wu, Qingbo Jia
-
Patent number: 11975073Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.Type: GrantFiled: June 26, 2023Date of Patent: May 7, 2024Assignees: PureTech LYT, Inc., Monash UniversityInventors: Daniel Kenneth Bonner, Rishab R. Shyam, Jamie Simpson, Christopher John Porter, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
-
Publication number: 20240141360Abstract: An isolated or purified AON for modifying pre-mRNA splicing in the Receptor for Advanced Glycation End-products (RAGE) to modulate splicing of the RAGE gene transcript or part thereof is provided.Type: ApplicationFiled: May 1, 2023Publication date: May 2, 2024Applicants: MONASH UNIVERSITY, MURDOCH UNIVERSITYInventors: Stephen WILTON, Merlin Christopher THOMAS, Carlos ROSADO, Raelene Jane PICKERING
-
Patent number: 11954823Abstract: A method and system for reconstructing magnetic resonance (MR) images, the method including the steps of: receiving an under-sampled MR image, the under-sampled MR image being transformed from under-sampled k-spaced data; classifying intensity of each pixel in the under-sampled MR image to one of a plurality of predetermined quantized values of intensity by using a neural network; and generating a reconstructed MR image based on the classified quantized value of the intensity for each pixel in the under-sampled MR image.Type: GrantFiled: May 14, 2019Date of Patent: April 9, 2024Assignee: Monash UniversityInventors: Kamlesh Pawar, Zhaolin Chen, Nadim Joni Shah, Gary Francis Egan
-
Publication number: 20240100134Abstract: The present invention relates to chimeric and fusion proteins and their compositions, and the use of such proteins and compositions in the prevention and/or treatment diseases or conditions requiring plasminogen supplementation. In one aspect, the invention provides a chimeric or fusion protein comprising plasminogen and an Fc region of an antibody.Type: ApplicationFiled: January 20, 2022Publication date: March 28, 2024Applicant: Monash UniversityInventors: James C. Whisstock, Ruby HP Law, Adam J. Quek, Christoph Hagemeyer, Mikael Martino, Guojie Wu, Yen-Zhen Lu
-
Patent number: 11938137Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.Type: GrantFiled: January 27, 2022Date of Patent: March 26, 2024Assignees: PureTech LYT, Inc., Monash UniversityInventors: Daniel Kenneth Bonner, Ketki Karanam, Sifei Han, Luojuan Hu, Christopher John Hamilton Porter, Tim Quach, Rishab R. Shyam, Jamie Simpson, Natalie Trevaskis
-
Publication number: 20240050573Abstract: The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.Type: ApplicationFiled: June 28, 2023Publication date: February 15, 2024Applicant: Monash UniversityInventors: Christopher John Porter, Jamie Simpson, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
-
Publication number: 20240048243Abstract: Apparatus including an optical signal generator, a data transmission path, and an optical signal receiver. Optical signal generator includes a coherent light source for generating a spectrum of carrier signals at different carrier frequencies, an optical demultiplexer that receives and separates the different carrier signals into separate optical paths, a pair of optical modulators located in each of the separate optical paths to modulate each different carrier signal with a data signal and produce an upper and lower sideband pair at each of the different carrier frequencies, and an optical interleaver to combine the upper and lower sideband pairs into an optical super-channel of interleaved sub-bands. Optical signal receiver includes a demodulator for extracting the data signals. Optical modulators are configured to reuse each carrier signal to transmit different data in each of the upper sideband and the lower sideband and increase the capacity of the super-channel. Also a method.Type: ApplicationFiled: December 17, 2021Publication date: February 8, 2024Applicant: MONASH UNIVERSITYInventors: William Peter Corcoran, Andreas Stefan Boes, Xingyuan Xu, Mengxi Tan, Chawaphon Prayoonyong, Arnan Deane Mitchell, David James Moss
-
Patent number: 11883497Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.Type: GrantFiled: August 29, 2018Date of Patent: January 30, 2024Assignees: PureTech LYT, Inc., Monash UniversityInventors: Daniel Kenneth Bonner, Ketki Karanam, James T. Mutamba, Rishab R. Shyam, Jamie Simpson, Sifei Han, Luojuan Hu, Christopher John Hamilton Porter, Tim Quach, Natalie Trevaskis
-
Patent number: 11878165Abstract: Closed-loop transcranial stimulation and monitoring is disclosed that includes generating a stimulation signal having a set of first oscillation parameters; applying the stimulation signal transcranially to a patient; monitoring the stimulation signal as applied to the patient; receiving a brain activity signal from the patient; generating a feedback signal based on the monitored stimulation signal as applied to the patient; and generating a modified activity signal by subtracting the feedback signal from the brain activity signal; determining one or more second oscillation parameters of the modified activity signal; and adjusting the set of first oscillation parameters of the stimulation signal based on the one or more second oscillation parameters of the modified activity signal. Closed-loop transcranial stimulation and monitoring is also disclosed in which the patient is engaged in a cognitive task.Type: GrantFiled: June 14, 2021Date of Patent: January 23, 2024Assignee: MONASH UNIVERSITYInventors: Paul B Fitzgerald, Caley M. Sullivan, Richard H. Thomson
-
Patent number: 11834663Abstract: The present invention relates to compositions, methods and kits for the treatment of fibrosis. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment of cardiac fibrosis. The invention provides a method of treating fibrosis in an individual comprising administering an inhibitor of insulin-regulated aminopeptidase (IRAP), thereby treating fibrosis.Type: GrantFiled: July 1, 2021Date of Patent: December 5, 2023Assignee: MONASH UNIVERSITYInventors: Siew Yeen Chai, Robert Widdop, Tracey Gaspari, Huey Wen Lee
-
Publication number: 20230338552Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.Type: ApplicationFiled: June 26, 2023Publication date: October 26, 2023Applicants: PureTech LYT, Inc., Monash UniversityInventors: Daniel Kenneth Bonner, Rishab R. Shyam, Jamie Simpson, Christopher John Porter, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
-
Patent number: 11780915Abstract: The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.Type: GrantFiled: September 11, 2018Date of Patent: October 10, 2023Assignee: MONASH UNIVERSITYInventors: Justin Hamilton, Mark Sleeman
-
Patent number: 11752116Abstract: This invention relates to methods of treating or preventing viral infections caused by flaviviruses, such as dengue virus, yellow fever virus, West Nile virus or Japanese encephalitis virus or infections caused by Chikungunya virus (CHIKV). The methods involve the administration of retinoic acid analogues to subjects who have, are suspected of having a flavivirus infection or infection with CHIKV, or to those who are at risk of becoming infected with a flavivirus or becoming infected with CHIKV.Type: GrantFiled: April 19, 2021Date of Patent: September 12, 2023Assignee: Monash UniversityInventors: Johanna Elisabeth Fraser, David Andrew Jans, Kylie Michelle Wagstaff
-
Publication number: 20230282944Abstract: A method of making a polyelectrolyte complex membrane separator for a Lithium-Sulfur battery to support lean electrolyte operation, comprising the steps of: forming polyelectrolyte complex nanoparticles by the addition of polyethylenimine (PEI) to tannic acid (TA); adding bovine serum albumin (BSA); purifying the nanoparticles; re-dispersing the nanoparticles in water to form a nanoparticle suspension; and dipcoating a polyolefin membrane in the nanoparticle suspension.Type: ApplicationFiled: July 23, 2021Publication date: September 7, 2023Applicant: MONASH UNIVERSITYInventors: Petar JOVANOVIC, Mahdokht SHAIBANI, Mainak MAJUMDER
-
Patent number: 11746396Abstract: An aluminium based alloy, and a method for production of components by additive manufacturing (AM) or other rapid solidification process with the alloy, is based on the alloy having a composition with from 2.01 wt % to 15.0 wt % manganese, from 0.3 wt % to 2.0 wt % scandium, with a balance apart from minor alloy elements and incidental impurities of aluminium.Type: GrantFiled: December 3, 2018Date of Patent: September 5, 2023Assignee: MONASH UNIVERSITYInventors: Paul Rometsch, Xinhua Wu, Qingbo Jia
-
Publication number: 20230272045Abstract: The present invention provides a fusion protein comprising interleukin-1 receptor antagonist (IL-1Ra) and an extracellular matrix (ECM) binding peptide which specifically binds to one or more or all extracellular matrix proteins selected from the group consisting of fibrinogen, fibronectin, vitronectin, tenascin C and heparan sulfate and use of the fusion protein to treat conditions in which administration of IL-1Ra is beneficial or in which IL-1R1 signalling needs to be dampened, to enhance tissue regeneration, particularly bone regeneration and/or wound repair or for treating wounds, burns and muscle, cartilage, tendon and bone disorders, to enhance the regenerative activity of growth factor administration or to reduce inflammation or desensitisation of a cell to growth factor stimulation.Type: ApplicationFiled: June 11, 2021Publication date: August 31, 2023Applicant: MONASH UNIVERSITYInventors: Mikaƫl MARTINO, Ziad JULIER
-
Patent number: D1003426Type: GrantFiled: January 7, 2021Date of Patent: October 31, 2023Assignee: MONASH UNIVERSITYInventors: Richard Morfuni, Daphne Flynn, Rowan Page, Mark C. Armstrong, Tuncay Alan, Jason Brenker
-
Patent number: D1019932Type: GrantFiled: January 7, 2021Date of Patent: March 26, 2024Assignee: Monash UniversityInventors: Richard Morfuni, Daphne Flynn, Rowan Page, Mark C. Armstrong, Tuncay Alan, Jason Brenker